NHS Dudley Health Economy Medicines Formulary
Home > 8 Malignant disease and immunosuppression > 8.1 Cytotoxic drugs > 8.1.5 Other antineoplastic drugs > Everolimus for the second-line treatment of advanced renal cell carcinoma - NICE TAG TA219

Everolimus for the second-line treatment of advanced renal cell carcinoma - NICE TAG TA219

1.1 Everolimus is not recommended for the second-line treatment of advanced renal cell carcinoma.

1.2 People currently receiving everolimus for the second-line treatment of advanced renal cell carcinoma should have the option to continue treatment until they and their clinician consider it appropriate to stop.

https://www.nice.org.uk/guidance/TA219

Site by Devopa
© Copyright 2019 NHS. All rights reserved.